FDA approves Lucentis (ranibizumab injection) for myopic choroidal neovascularisation

Roche announced today that the US Food and Drug Administration (FDA) has approved Lucentis ® (ranibizumab injection) 0.5 mg for the treatment of patients with myopic choroidal neovascularisation (mCNV), a complication of severe near-sightedness that can lead to blindness.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news

Related Links:

We examined the fixation behaviour of change detectors and non-detectors monitoring dynamic scenes. One hundred ...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news
Police worldwide regularly review closed-circuit television (CCTV) evidence in investigations. This research found that London police experts who work in a full-time "Super-Recogniser Unit" and front line police identifiers regularly making suspect identif...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news
Change blindness is the striking inability to detect seemingly obvious changes that occur between views of a scene. The current study assessed perceptual load as a factor that may affect change blindness for human faces. The study had participants (n = 103...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news
Different variants of the obligate intracellular bacterial pathogen Chlamydia trachomatis cause the diseases trachoma and chlamydia. The trachoma strains cause chronic infections of the conjunctival epithelium and an intense inflammatory response that can lead to corneal damage, and trachoma is the most common cause of infectious blindness. The Chlamydia strains...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Tags: Commentaries Source Type: research
CONCLUSION: The causes of visual impairment are manifold. Loss of vision is often the combined effect of multiple pathological factors. The etiology of visual impair- ment is thus a more complex matter than is commonly assumed. PMID: 31196384 [PubMed - in process]
Source: Deutsches Arzteblatt International - Category: General Medicine Tags: Dtsch Arztebl Int Source Type: research
Publication date: Available online 15 June 2019Source: Pharmacological ResearchAuthor(s): S. Priya Narayanan, Esraa Shosha, Chithra D PalaniAbstractDiabetic Retinopathy (DR), is a significant public health issue and the leading cause of blindness in working-aged adults worldwide. The vision loss associated with DR affects patients’ quality of life and has negative social and psychological effects. In the past, diabetic retinopathy was considered a vascular disease; however, it is now recognized to be a neuro-vascular disease of the retina. Current therapies for DR, such as laser photocoagulation and anti-VEGF therapy...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Conclusion: Our study revealed a strong association between a variant in COL8A1 (rs13095226) and exudative AMD development. PMID: 31191752 [PubMed - in process]
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
GLAUCOMA affects more than 64 million people worldwide, and it ’s one of the largest causes of blindness in the world. While it’s undeniable that regular eye tests can help detect early signs, there are lots of surprising facts about the condition that are not as evident.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Abstract Light-activated chimeric GPCRs, termed OptoXRs, can elicit cell signalling responses with the high spatial and temporal precision of light. In recent years, an expanding OptoXR toolkit has been applied to, for example, dissect neural circuits in awake rodents, guide cell migration during vertebrate development and even restore visual responses in a rodent model of blindness. OptoXRs have been further developed through incorporation of highly sensitive photoreceptor domains and a plethora of signalling modules. The availability of new high-resolution structures of GPCRs and a deeper understanding of GPCR f...
Source: Current Opinion in Structural Biology - Category: Biology Authors: Tags: Curr Opin Struct Biol Source Type: research
Conclusion: Our US/PA imaging approach can inform preclinical studies of stem cell therapies for glaucoma treatment, motivating further development of this theranostic imaging tool for ophthalmic applications.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
More News: Blindness | Food and Drug Administration (FDA) | Lucentis | Opthalmology | Pharmaceuticals | Ranibizumab Injection